Clinical Trial Update: Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated the safety, pharmacokinetics, and pharmacodynamics of NNC126-0083 in adults with growth hormone deficiency; the study has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• NNC126-0083

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 2 | Status: COMPLETED